NCT03544723View on ClinicalTrials.gov

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

June 30, 2022

Study Completion Date

December 31, 2022

Conditions
Solid TumorLymphoma
Interventions
DRUG

Ad-p53

Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors. Immunotherapy. Gene Therapy.

Trial Locations (3)

60612

RECRUITING

Rush University Cancer Center, Chicago

Illinois

RECRUITING

"Robert H. Lurie Comprehensive Cancer Center , Northwestern University"

07960

RECRUITING

Morristown Medical Center, Morristown

Sponsors

Lead Sponsor

MultiVir, Inc.
All Listed Sponsors
lead

MultiVir, Inc.

INDUSTRY